Nate Massari brings twenty-five years of experience across strategy, pipeline product development, marketing, sales leadership, and corporate development in the biopharmaceutical industry. As Chief Business Officer, he leads business operations, early commercialization, growth and partnership strategies globally.
Before joining Anjarium, Nate was Executive Vice President of Rare Disease Operations at Aytu BioPharma, where he advanced treatments for rare genetic vascular conditions. Prior to that, he co-founded Rumpus Therapeutics, focusing on pediatric onset orphan diseases, which later integrated into Aytu upon the acquisition of its lead program, AR101 (enzastaurin).
Nate's extensive leadership experience includes key roles at Centocor / Johnson & Johnson, MedImmune / AstraZeneca, Endo Pharmaceuticals, and Cencora (formerly AmerisourceBergen). He has orchestrated business development transactions, deploying over $6B in capital, and has a strong track record in rare disease management, including the launch of pediatric inflammatory bowel disease indications and leading orphan drug pediatric endocrinology franchises. He began his career in management consulting within the Health & Life Sciences practice at Accenture.
He holds a BA from Princeton University and earned his MBA from the Wharton School at the University of Pennsylvania.
